Previous 10 | Next 10 |
Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...
The release of the latest read on consumer inflation, which showed the June figure jumping 9.1% from last year, put pressure on stock prices on Wednesday. Investors worried that the Federal Reserve would ratchet up its interest rate hikes even more, raising the chances of an eventual recess...
Shares of the next-generation cell therapy company Atara Biotherapeutics (NASDAQ: ATRA) are getting hammered today. Specifically, the clinical-stage biotech's stock was down by an unsightly 54% as of 3:36 p.m. ET Wednesday. What's weighing on Atara's share price today? Prior to ...
Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...
Atara Biotherapeutics ( NASDAQ: ATRA ) shed ~56% to record its biggest intraday loss after Stifel downgraded the Clinical-stage biotech on Wednesday in reaction to its Phase 2 interim data for ATA188, a CAR T immunotherapy for progressive multiple sclerosis. The company ...
Humanigen HGEN -68% as trial for COVID-19 therapy fails . Atara Biotherapeutics ATRA -46% on interim analysis of phase 2 study for multiple sclerosis candidate. TherapeuticsMD TXMD -41% as merger agreement ends . Helius Medical Technologies ( HSDT...
Atara Biotherapeutics ( NASDAQ: ATRA ) stock plunged ~27% after hours as the company announced completion of its interim analysis of its phase 2 EMBOLD study for ATA188, a CAR-T immunotherapy for progressive multiple sclerosis. Shares of the clinical-stage biotech had ...
Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023 Conference Cal...
Clinical-stage biotech Atara Biotherapeutics ( NASDAQ: ATRA ) surged ~16% as the company plans to report interim data on Tuesday from its Phase 2 EMBOLD study for ATA188, a CAR T immunotherapy for progressive multiple sclerosis. About ~1.2M shares have changed hand...
Live Conference Call and Webcast at 5:00 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...